Matched-cohort study shows improved hematologic and organ responses in AL amyloidosis, suggesting a beneficial treatment approach.
A frequency-adjusted Dara-based regimen induces significantly faster and deeper hematologic and organ responses compared to BD in newly diagnosed AL amyloidosis which offers a promising personalized approach to reduce treatment burden and adverse events while maintaining high efficacy, supporting its integration into clinical practice for a broader patient population.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Annals of Medicine